Comparison of Plasma Drug Levels of Triomune 40 With Those of the Originator Products - Full Text View

Sponsors and Collaborators:	Makerere University Department of Foreign Affairs, Ireland
Information provided by:	Makerere University
ClinicalTrials.gov Identifier:	NCT00455585

Purpose

This study aims to compare the steady state pharmacokinetics of stavudine, lamivudine, and nevirapine in HIV positive Ugandan patients taking Triomune 40 with the pharmacokinetics of the originator products known as Viramune, Epivir and Zerit 40.

Condition	Intervention	Phase
HIV Infections	Drug: nevirapine, stavudine, lamivudine	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Dose Comparison, Crossover Assignment, Bio-equivalence Study
Official Title:	Comparison of the Steady State Pharmacokinetics of Nevirapine, Stavudine Plus Lamivudine in HIV Positive Ugandan Patients Taking Triomune 40 With the Pharmacokinetics of the Originator Products.

Resource links provided by NLM:

MedlinePlus related topics: AIDS

Drug Information available for: Nevirapine Lamivudine Stavudine

U.S. FDA Resources

Further study details as provided by Makerere University:

Primary Outcome Measures:

Pharmacokinetics of nevirapine, stavudine and lamivudine

Secondary Outcome Measures:

Safety aand tolerability of nevirapine, stavudine and lamivudine
Pharmacogenomics of Ugandan subjects

Estimated Enrollment:	18
Study Start Date:	January 2007
Study Completion Date:	November 2007
Primary Completion Date:	May 2007 (Final data collection date for primary outcome measure)

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age over eighteen years Ability to provide full informed written consent Confirmed diagnosis of HIV infection On ARV therapy with Triomune 40

Exclusion Criteria:

Haemoglobin < 8g/dl Liver and renal function tests > 3 times the upper limit of normal Pregnancy Use of know inhibitors or inducers of cytochrome P450 or P-glycoprotein. Use of herbal medications Weight <60kg Intercurrent illness

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00455585

Locations

Uganda
Makerere University, Infectious Diseases Insititute
Kampala, Uganda, 22418

Sponsors and Collaborators

Makerere University

Department of Foreign Affairs, Ireland

Investigators

Principal Investigator:	Concepta Merry, PhD	Trinity College Dublin
Study Director:	Keith McAdam	Infectious Diseases Institute, Makerere University

More Information

Publications:

JA Gogtay, V.M., VG Nayak, PV Bodhe, A Dasgupta, V Srivatsan, G Vaidyanathan, KC Patel. A pharmacokinetic evaluation of lamivudine, stavudine and nevirapine given as a fixed dose combination pill versus the same three drugs given safely in healthy human volunteers. in 6th International Congress on Drug Therapy in HIV Infection. 2002. Glasgow,UK. 16.

Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liegeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngole E, Delaporte E. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004 Jul 3-9;364(9428):29-34.

Hosseinipour M C, C.A., Kanyama C, Mshali I. Pharmacokinetic Comparison of Generic and Trade Formulations of Lamivudine, Stavudine and Nevirapine in HIV-infected Malawian Subjects. in 12th Conference on Retroviruses and Opportunistic Infections. 2005. Boston. 17.

Responsible Party:	Infectious Diseases Institute ( Concepta Merry )
Study ID Numbers:	CPR001
Study First Received:	April 2, 2007
Last Updated:	February 7, 2008
ClinicalTrials.gov Identifier:	NCT00455585 History of Changes
Health Authority:	Uganda: National Council for Science and Technology

Keywords provided by Makerere University:

Pharmacokinetics
Antiretrovirals
Uganda
HIV
Treatment Experienced

Study placed in the following topic categories:

Antimetabolites
Anti-Infective Agents
Sexually Transmitted Diseases, Viral
Stavudine
Anti-HIV Agents
Acquired Immunodeficiency Syndrome
Lamivudine
Antiviral Agents
Immunologic Deficiency Syndromes

Reverse Transcriptase Inhibitors
Virus Diseases
Nevirapine
HIV Seropositivity
Anti-Retroviral Agents
HIV Infections
Sexually Transmitted Diseases
Retroviridae Infections

Additional relevant MeSH terms:

Antimetabolites
Anti-Infective Agents
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Stavudine
Molecular Mechanisms of Pharmacological Action
Lamivudine
Infection
Reverse Transcriptase Inhibitors
Anti-Retroviral Agents
Therapeutic Uses
Retroviridae Infections
Nucleic Acid Synthesis Inhibitors

RNA Virus Infections
Anti-HIV Agents
Immune System Diseases
Acquired Immunodeficiency Syndrome
Enzyme Inhibitors
Antiviral Agents
Immunologic Deficiency Syndromes
Pharmacologic Actions
Virus Diseases
Nevirapine
HIV Infections
Sexually Transmitted Diseases
Lentivirus Infections

ClinicalTrials.gov processed this record on September 10, 2009